Bridgebio Pharma, Inc. (BBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$74.84-0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Primary pillar under pressure — Manage operating losses and improve operating income: metric not reported.
BridgeBio grows revenue fast from Attruby and new drugs. Revenue rose from $116.6M to $194.5M in one year. They plan three big drug launches soon. The company is cutting losses, improving operating income from -$139.6M to -$106M.
The company still loses money and faces payer risks. Operating losses remain large despite some improvement. Capital raises dilute shareholders and may hurt stock value.
The stock price is about 16% above our fair value near $67. Analysts expect revenue to nearly double next year. Our fair value is 34% below the Street median, so the market is optimistic.
Breaks if: Stock repurchase program not executed as planned in 2026-Q1
Breaks if: operating income worse than -$105.96 million in 2026-Q1
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment focused on the biotechnology sector. The current thesis state reflects a cautious optimism due to recent revenue growth and potential product launches, but it is tempered by earnings misses and management volatility.
The market seems to be pricing in a low expectations gap, suggesting that investors are not overly optimistic about BBIO's near-term performance. The valuation indicates a durable premium compared to peers, which may reflect confidence in its long-term growth potential despite current losses.
Management is on track with revenue growth driven by Attruby and has multiple product launches planned. However, the company has a history of earnings misses, which raises concerns about near-term performance and execution.
The future performance of BBIO hinges on its ability to meet or exceed guidance in upcoming earnings calls and the broader healthcare sector's momentum. Additionally, any shifts in economic conditions, such as a weakening jobs report, could negatively impact investor sentiment.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company advanced its pipeline with new drug approvals. However, it also reported a miss in its latest earnings. This mixed performance creates uncertainty around future growth.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Control operating expenses while investing in commercialization and late-stage development to improve operating income over time.
Breaks if: revenue falls below $194.5 million in 2026-Q1
Continue to expand revenue by increasing sales of Attruby and preparing for three additional potential blockbuster product launches over the next 12 months.
Stated as a priority in 2 of last 2 quarters. Total revenues grew from $116.6 million in 2025-Q1 to $194.5 million in 2026-Q1, and further to $243.7 million in 2026-Q2, driven primarily by Attruby net product revenue growth. Management has emphasized preparing for three additional potential blockbuster product launches over the next 12 months, and the revenue trajectory is delivering consistent growth aligned with this priority.
“Attruby net product revenue of $222.4 million with growth led by treatment-naïve segment; preparing for three potential approvals in three diseases.”
“Strong prescribing growth and patient persistence driving continued commercial momentum for Attruby; preparing for three critical launches.”
In the next 1 to 3 years, BBIO's trajectory will depend on successful product launches and management execution amidst a volatile earnings environment. Not investment advice.